Derek Archila

Stock Analyst at Wells Fargo

(2.22)
# 728
Out of 4,460 analysts
126
Total ratings
41.3%
Success rate
-4.99%
Average return

38 Stocks

Zentalis Pharmaceuticals
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $29$9
Current: $4.14
Upside: +117.39%
Apellis Pharmaceuticals
May 23, 2024
Maintains: Equal-Weight
Price Target: $57$48
Current: $40.07
Upside: +19.79%
Annexon
May 15, 2024
Maintains: Overweight
Price Target: $12$10
Current: $5.07
Upside: +97.24%
C4 Therapeutics
May 9, 2024
Maintains: Equal-Weight
Price Target: $7$8
Current: $4.08
Upside: +96.08%
Arvinas
May 9, 2024
Maintains: Overweight
Price Target: $63$60
Current: $24.82
Upside: +141.74%
Zymeworks
May 3, 2024
Maintains: Overweight
Price Target: $14$12
Current: $8.52
Upside: +40.85%
Ascendis Pharma
May 3, 2024
Maintains: Overweight
Price Target: $260$262
Current: $123.19
Upside: +112.68%
Rhythm Pharmaceuticals
Apr 18, 2024
Maintains: Overweight
Price Target: $53$52
Current: $41.39
Upside: +25.63%
AnaptysBio
Apr 11, 2024
Initiates: Overweight
Price Target: $56
Current: $22.89
Upside: +144.65%
Cabaletta Bio
Mar 22, 2024
Maintains: Overweight
Price Target: $34$35
Current: $8.35
Upside: +319.16%
Acelyrin
Mar 21, 2024
Maintains: Equal-Weight
Price Target: $11$13
Current: $4.20
Upside: +209.52%
MorphoSys AG
Mar 14, 2024
Downgrades: Equal-Weight
Price Target: $17$18
Current: $18.12
Upside: +0.72%
Ventyx Biosciences
Mar 12, 2024
Upgrades: Overweight
Price Target: $7$16
Current: $2.75
Upside: +481.82%
argenx SE
Feb 20, 2024
Maintains: Overweight
Price Target: $472$478
Current: $377.96
Upside: +26.47%
Nurix Therapeutics
Feb 16, 2024
Maintains: Overweight
Price Target: $23$20
Current: $18.44
Upside: +8.46%
Kymera Therapeutics
Dec 19, 2023
Downgrades: Equal-Weight
Price Target: $26
Current: $31.20
Upside: -16.67%
Blueprint Medicines
Dec 19, 2023
Maintains: Overweight
Price Target: $86$115
Current: $106.71
Upside: +7.77%
Kezar Life Sciences
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $4$2
Current: $0.65
Upside: +205.39%
Celldex Therapeutics
Nov 10, 2023
Upgrades: Equal-Weight
Price Target: $27
Current: $34.66
Upside: -22.10%
Immunovant
Sep 27, 2023
Maintains: Overweight
Price Target: $33$48
Current: $26.19
Upside: +83.28%
Morphic Holding
Apr 25, 2023
Maintains: Overweight
Price Target: $67$80
Current: $26.16
Upside: +205.81%
Exelixis
Mar 9, 2023
Initiates: Overweight
Price Target: $23
Current: $21.56
Upside: +6.68%
Incyte
Jan 3, 2023
Maintains: Equal-Weight
Price Target: $72$75
Current: $61.44
Upside: +22.07%
Monte Rosa Therapeutics
Jan 3, 2023
Upgrades: Overweight
Price Target: $19
Current: $3.54
Upside: +436.72%
Esperion Therapeutics
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $2.72
Upside: -
Lumos Pharma
Mar 11, 2021
Upgrades: Buy
Price Target: n/a
Current: $2.20
Upside: -
Inventiva
Aug 4, 2020
Initiates: Buy
Price Target: n/a
Current: $2.62
Upside: -
Genfit
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.15
Upside: -
Galapagos NV
Jul 10, 2020
Downgrades: Hold
Price Target: n/a
Current: $25.84
Upside: -
ONEOK
Apr 15, 2020
Reiterates: Buy
Price Target: n/a
Current: $80.06
Upside: -
Amarin Corporation
Mar 31, 2020
Maintains: Hold
Price Target: n/a
Current: $0.73
Upside: -
DBV Technologies
Mar 17, 2020
Downgrades: Hold
Price Target: $36$12
Current: $0.98
Upside: +1,126.24%
Vanda Pharmaceuticals
Dec 11, 2018
Downgrades: Perform
Price Target: n/a
Current: $6.34
Upside: -
Heron Therapeutics
Jun 22, 2018
Maintains: Outperform
Price Target: n/a
Current: $3.42
Upside: -
UroGen Pharma
Nov 15, 2017
Maintains: Outperform
Price Target: n/a
Current: $16.87
Upside: -
Perrigo Company
Sep 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $25.55
Upside: -
Pacira BioSciences
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $28.19
Upside: -
Teva Pharmaceutical
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $17.01
Upside: -